For research use only. Not for therapeutic Use.
Runcaciguat is an orally active stimulator of soluble guanylate cyclase, and is used in the research of cardiovascular and renal diseases combined with selective partial adenosine A1 receptor agonists[1].
| Catalog Number | I019112 |
| CAS Number | 1402936-61-1 |
| Synonyms | (3S)-3-[4-chloro-3-[[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino]phenyl]-3-cyclopropylpropanoic acid |
| Molecular Formula | C23H22Cl2F3NO3 |
| Purity | ≥95% |
| InChI | InChI=1S/C23H22Cl2F3NO3/c1-12(23(26,27)28)21(14-4-7-16(24)8-5-14)22(32)29-19-10-15(6-9-18(19)25)17(11-20(30)31)13-2-3-13/h4-10,12-13,17,21H,2-3,11H2,1H3,(H,29,32)(H,30,31)/t12-,17+,21+/m1/s1 |
| InChIKey | NCRMKIWHFXSBGZ-CNBXIYLPSA-N |
| SMILES | CC(C(C1=CC=C(C=C1)Cl)C(=O)NC2=C(C=CC(=C2)C(CC(=O)O)C3CC3)Cl)C(F)(F)F |
| Reference | [1]. Barbara ALBRECHT-KÜPPER, et al. Selective partial adenosine a1 receptor agonists in combination with soluble guanylyl cyclase (sgc) stimulators and/or activators. WO2018153899A1. |
